文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

CAR-T细胞毒性分级系统比较:ASTCT分级系统的应用与管理启示

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
PubMed 文献 · Blood Adv · 2020-01-01

该研究在53例接受1928z CAR-T治疗的B-ALL患者和49例接受axi-cel或tisagenlecleucel治疗的DLBCL患者中比较了ASTCT分级与其他分级系统。按ASTCT标准,82%患者发生CRS,50%发生ICANS;各系统对CRS和ICANS诊断一致率分别为99%和91%,但逐级分析仅25%和54%患者分级相同。DLBCL患者中不同指南对托珠单抗和激素的推荐可能导致过度治疗或延迟治疗。

要点

  • ASTCT分级下82%患者发生CRS,50%发生ICANS。
  • 各分级系统对CRS和ICANS诊断一致率高,但逐级分级一致率低。
  • 不同指南对托珠单抗和激素的推荐差异可能导致过度治疗或延迟治疗。

核心结论

  • 不同分级系统对CRS和ICANS的诊断一致率高,但逐级分级一致性低,导致最终分级不一致。
  • 基于单一产品和不同分级系统的指南不能普遍适用,可能导致过度治疗或延迟治疗。
  • 建议在临床试验和实践中使用统一分级,并制定与产品特异性适应症配对的管理指南。

研究设计与样本

  • 比较ASTCT分级系统与其他分级评分在两组成人患者中的应用。
  • B-ALL组53例接受1928z CAR-T细胞治疗(NCT01044069)。
  • DLBCL组49例在FDA批准后接受axi-cel或tisagenlecleucel治疗。

主要发现

  • 按ASTCT分级,82%患者发生CRS:B-ALL组87%,DLBCL组77%(axi-cel 86%,tisagenlecleucel 54%)。
  • 按ASTCT分级,50%患者发生ICANS:B-ALL组55%,DLBCL组45%(axi-cel 55%,tisagenlecleucel 15%)。
  • 所有分级系统对CRS和ICANS诊断一致率分别为99%和91%。
  • 逐级分析中,仅25%和54%患者在各系统间CRS和ICANS分级相同。
  • DLBCL患者中,不同指南对托珠单抗和激素的推荐可能导致过度治疗或延迟治疗。

关键数值与推荐

  • ASTCT分级下CRS发生率82%,ICANS发生率50%。
  • 各系统CRS诊断一致率99%,ICANS诊断一致率91%。
  • 逐级分级一致率:CRS 25%,ICANS 54%。

临床怎么用

  • 临床中应采用统一的分级系统评估CAR-T相关毒性。
  • 管理指南应与具体产品适应症配对使用,避免过度治疗或延迟治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Various grading systems are currently used for chimeric antigen receptor (CAR) T-cell-related toxicity, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). We compared the recently proposed American Society for Transplantation and Cellular Therapy (ASTCT) grading system to other grading scores in 2 populations of adults: patients (n = 53) with B-cell acute lymphoblastic leukemia (B-ALL) treated with 1928z CAR T-cells (clinicaltrials.gov #NCT01044069), and patients (n = 49) with diffuse large B-cell lymphoma (DLBCL) treated with axicabtagene-ciloleucel (axi-cel) or tisagenlecleucel after US Food and Drug Administration approval. According to ASTCT grading, 82% of patients had CRS, 87% in the B-ALL and 77% in the DLBCL groups (axi-cel: 86%, tisagenlecleucel: 54%), whereas 50% of patients experienced ICANS, 55% in the B-ALL and 45% in the DLBCL groups (axi-cel: 55%, tisagenlecleucel: 15%). All grading systems agreed on CRS and ICANS diagnosis in 99% and 91% of cases, respectively. However, when analyzed grade by grade, only 25% and 54% of patients had the same grade in each system for CRS and ICANS, respectively, as different systems score symptoms differently (upgrading or downgrading their severity), leading to inconsistent final grades. Investigation of possible management implications in DLBCL patients showed that different recommendations on tocilizumab and steroids across current guidelines potentially result in either overtreating or delaying treatment. Moreover, because these guidelines are based on single products and different grading systems, they cannot be universally applied. To avoid discrepancies in assessing and managing toxicities of different products, we propose that unified grading be used across clinical trials and in practice and that paired management guidelines with product-specific indications be developed.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pennisi M, Jain T, Santomasso BD, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020. PMID: 32084260. doi:10.1182/bloodadvances.2019000952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。